BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 26924195)

  • 21. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
    Ibrahim AM; Wang YH
    World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.
    Albury TM; Pandey V; Gitto SB; Dominguez L; Spinel LP; Talarchek J; Klein-Szanto AJ; Testa JR; Altomare DA
    Neoplasia; 2015 Feb; 17(2):175-82. PubMed ID: 25748236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging Treatment Strategies in Pancreatic Cancer.
    Trunk A; Miotke L; Nevala-Plagemann C; Verdaguer H; Macarulla T; Garrido-Laguna I
    Pancreas; 2021 Jul; 50(6):773-787. PubMed ID: 34398070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy for pancreatic cancer: A 2020 update.
    Schizas D; Charalampakis N; Kole C; Economopoulou P; Koustas E; Gkotsis E; Ziogas D; Psyrri A; Karamouzis MV
    Cancer Treat Rev; 2020 Jun; 86():102016. PubMed ID: 32247999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma".
    Borazanci E; Dang CV; Robey RW; Bates SE; Chabot JA; Von Hoff DD
    Clin Cancer Res; 2017 Apr; 23(7):1629-1637. PubMed ID: 28373361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of KRAS Mutation in Acinar and Langerhans Islet Cells of Patients With Pancreatic Ductal Adenocarcinoma.
    Wang Z; Zhang C; Nagee K; Mohammadi A; Monteiro C
    Pancreas; 2016 Mar; 45(3):337-41. PubMed ID: 26474433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions.
    Nagawkar SS; Abu-Funni S; Simon E; Bick T; Prinz E; Sabo E; Ben-Izhak O; Hershkovitz D
    Pancreas; 2016 Jul; 45(6):876-81. PubMed ID: 26646269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
    Bauer C; Kühnemuth B; Duewell P; Ormanns S; Gress T; Schnurr M
    Cancer Lett; 2016 Oct; 381(1):259-68. PubMed ID: 26968250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mouse Models of Pancreatic Ductal Adenocarcinoma.
    Ponz-Sarvise M; Tuveson DA; Yu KH
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):609-17. PubMed ID: 26226900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
    Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The KRAS-PDEδ interaction is a therapeutic target.
    Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pancreatic cancer, treatment options, and GI-4000.
    Hartley ML; Bade NA; Prins PA; Ampie L; Marshall JL
    Hum Vaccin Immunother; 2014; 10(11):3347-53. PubMed ID: 25585100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetics and biology of pancreatic ductal adenocarcinoma.
    Ying H; Dey P; Yao W; Kimmelman AC; Draetta GF; Maitra A; DePinho RA
    Genes Dev; 2016 Feb; 30(4):355-85. PubMed ID: 26883357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
    Liao J; Hwang SH; Li H; Yang Y; Yang J; Wecksler AT; Liu JY; Hammock BD; Yang GY
    Cancer Lett; 2016 Feb; 371(2):187-93. PubMed ID: 26683769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole genomes redefine the mutational landscape of pancreatic cancer.
    Waddell N; Pajic M; Patch AM; Chang DK; Kassahn KS; Bailey P; Johns AL; Miller D; Nones K; Quek K; Quinn MC; Robertson AJ; Fadlullah MZ; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Wani S; Wilson PJ; Markham E; Cloonan N; Anderson MJ; Fink JL; Holmes O; Kazakoff SH; Leonard C; Newell F; Poudel B; Song S; Taylor D; Waddell N; Wood S; Xu Q; Wu J; Pinese M; Cowley MJ; Lee HC; Jones MD; Nagrial AM; Humphris J; Chantrill LA; Chin V; Steinmann AM; Mawson A; Humphrey ES; Colvin EK; Chou A; Scarlett CJ; Pinho AV; Giry-Laterriere M; Rooman I; Samra JS; Kench JG; Pettitt JA; Merrett ND; Toon C; Epari K; Nguyen NQ; Barbour A; Zeps N; Jamieson NB; Graham JS; Niclou SP; Bjerkvig R; Grützmann R; Aust D; Hruban RH; Maitra A; Iacobuzio-Donahue CA; Wolfgang CL; Morgan RA; Lawlor RT; Corbo V; Bassi C; Falconi M; Zamboni G; Tortora G; Tempero MA; ; Gill AJ; Eshleman JR; Pilarsky C; Scarpa A; Musgrove EA; Pearson JV; Biankin AV; Grimmond SM
    Nature; 2015 Feb; 518(7540):495-501. PubMed ID: 25719666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.
    de Mestier L; Danset JB; Neuzillet C; Rebours V; Cros J; Soufir N; Hammel P
    Endocr Relat Cancer; 2016 Oct; 23(10):T57-67. PubMed ID: 27511924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pancreatic ductal adenocarcinoma harboring microsatellite instability / DNA mismatch repair deficiency. Towards personalized medicine.
    Lupinacci RM; Bachet JB; André T; Duval A; Svrcek M
    Surg Oncol; 2019 Mar; 28():121-127. PubMed ID: 30851885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer.
    Kajihara M; Takakura K; Kanai T; Ito Z; Matsumoto Y; Shimodaira S; Okamoto M; Ohkusa T; Koido S
    World J Gastroenterol; 2016 May; 22(18):4446-58. PubMed ID: 27182156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.